National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

About this update from Sonoma Pharmaceuticals, Inc.

[{"type":"text","content":"BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has earned the National Rosacea Society (NRS) Seal of Acceptance.","length":499,"tagName":"p"},{"type":"text","content":"The NRS introduced the Seal of Acceptance program to identify gentle skin care and cosmetic products that have been clinically tested, expertly evaluated and found to be unlikely to irritate sensitive rosacea skin - providing valuable guidance to those searching for skin care and cosmetics that may be suitable for people with rosacea.","length":336,"tagName":"p"},{"type":"text","content":""We are honored to receive this recognition from the National Rosacea Society," said Amy Trombly, CEO of Sonoma Pharmaceuticals. Reliefacyn, which has previously received the National Eczema Association Seal of Acceptance and the National Psoriasis Foundation Seal of Recognition, exemplifies the versatility of Sonoma's Microcyn-based products and the Company's commitment to provide safe and effective skincare solutions to the many people living with chronic skin conditions such as eczema, psoriasis and rosacea."","length":540,"tagName":"p"},{"type":"text","content":"About Sonoma Pharmaceuticals, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal ...

More updates from Sonoma Pharmaceuticals, Inc.